arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Editas Medicine, Inc.

EDIT
$2.67 ▼ -0.26 (-8.70%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
48 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Editas Medicine, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $318.5M
Dividend Yield
Revenue Growth 232.3%
Op. Margin -156.0%
ROIC -9.5%
FCF / Share $-0.25
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity 0.46
info Valuation on last close. End-of-day price, Sep 23, 2026.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.89M
↑ +232.3%
Net Income Profit after all expenses
$-24.98M
↑ +67.2%
Operating Margin Operating profit as % of sales
-156.0%
↓ -397.8% 0th
FCF / Share Free cash flow per share
$-0.25
↓ -5.2%
Long-Term Debt Long-term obligations
$48.24M
↑ +2.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
0
Financial Health
17
Cash Quality
67

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 48 quarters